Advertisement

HindustanTimes Sat,30 Aug 2014

India will achieve 7% plus growth soon: Ratan Tata

PTI  Singapore, March 15, 2013
First Published: 14:57 IST(15/3/2013) | Last Updated: 15:04 IST(15/3/2013)

Ratan Tata said on Friday that he expects India to re-establish its economic growth at 7% plus rate in the next couple of years but it will not be able to achieve over 8% it had prior to the 2008-09 global financial crisis.

Advertisement

The chairman emeritus of the Tata Group said that the recent steps by the government have restored investors' confidence in the country, but more needs to be done.

He noted that efforts to control inflation, scams, and other issues, resulted in the Indian economic growth slowing down to 5% or below.

"To many, it has been like a recession," he added.

"I think we will re-establish at 7% plus growth rate in couple of years driven by the fact that we have got pent up demand in the country.

"But it is not going to be as attractive as it has been in the past," said Tata, who retired from the group last year, during a dialogue session with students at the Singapore Management University (SMU).

Responding to a question on recent economic boosting measures in the Indian Budget for 2013-14, he said: "One must ask: is it enough or is too late. My own feeling is that some of the confidence in the Indian economy, perhaps amongst investors, is restored.

"But there is a lot more that needs to be done if India is to be moving back to the visibility and the attraction that it had some years ago.

"May be just moderate moves are not going to be enough to undo the damage that has been done over the last few years."

The measures in the most recent budget has "are very moderate and perhaps, signs of moving into the right direction," he told some 500 students, academics and members of the business community at the dialogue session.


Advertisement
more from Business

Sun-Ranbaxy deal: CCI raises concerns about molecules mkt

The Competition Commission, which has put the multi-billion dollar Sun-Ranbaxy deal for public scrutiny, said on Friday the major issue is whether the combination would result in high market concentration of certain molecules.

markets
Advertisement
Most Popular
Advertisement
Advertisement
Copyright © 2014 HT Media Limited. All Rights Reserved